List of Excipients in Branded Drug GAINEXTRA HAIR REGROWTH TREATMENT FOR MEN 5%

« Back to Dashboard

Generic Drugs Containing GAINEXTRA HAIR REGROWTH TREATMENT FOR MEN 5%

Company	Ingredient	NDC	Excipient
Gabar Health Sciences Corp	minoxidil 5%	82429-261	ISOPROPYL ALCOHOL
Gabar Health Sciences Corp	minoxidil 5%	82429-261	PROPYLENE GLYCOL
Gabar Health Sciences Corp	minoxidil 5%	82429-261	WATER

What are the Most Frequently-Used Excipients in GAINEXTRA HAIR REGROWTH TREATMENT FOR MEN 5%?

# Of NDCs	Excipient
1	ISOPROPYL ALCOHOL
1	PROPYLENE GLYCOL
1	WATER

Gainextra Hair Regrowth Treatment for Men 5%: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 16, 2026

Gainextra Hair Regrowth Treatment for Men 5% is positioned as an over-the-counter topical minoxidil product. Its commercial opportunity is unlikely to come from active-ingredient exclusivity because 5% minoxidil is an established OTC category with no meaningful compound patent barrier. Value can instead be created through excipient selection, reduced irritation, improved cosmetic acceptability, dosing convenience, packaging, combination products, and differentiated regulatory claims.

The strongest commercial pathway is a premium topical product that improves adherence without changing the approved minoxidil concentration or making unsubstantiated hair-growth claims. A low-irritation, low-residue formulation, preferably in a unit-dose foam, pump spray, or metered applicator, offers more differentiation than a conventional alcohol-and-propylene-glycol solution.

What is Gainextra Hair Regrowth Treatment for Men 5%?

Gainextra 5% is understood to be a topical minoxidil product for male pattern hair loss. The standard active ingredient is minoxidil 5%, generally supplied as a liquid solution or foam.

Product attribute	Commercial assessment
Active ingredient	Minoxidil 5%
Therapeutic category	OTC topical hair regrowth treatment
Target population	Adult men with androgenetic alopecia
Typical dosage form	Topical solution or foam
Administration	Applied directly to the scalp, commonly twice daily for solution products
Regulatory route	FDA OTC drug framework or applicable monograph pathway
Compound patent risk	Low
Formulation differentiation	Moderate to high
Biosimilar exposure	None
Orange Book exposure	Generally not applicable to monograph OTC products

FDA labeling for topical minoxidil products generally limits use to adults and instructs consumers to apply the product to the affected scalp area. Products are not intended for sudden or patchy hair loss, hair loss associated with childbirth, or unexplained hair loss without medical evaluation.[1]

What excipients are commonly used in 5% minoxidil products?

Conventional 5% minoxidil solutions commonly use ethanol, propylene glycol, purified water, and pH-adjusting or stabilizing components. Minoxidil has limited water solubility, so solvent selection is central to maintaining a clear, stable product.

Conventional solution excipients

Excipient class	Typical function	Commercial benefit	Main concern
Ethanol	Primary solvent and penetration enhancer	Rapid drying	Stinging, flammability, scalp dryness
Propylene glycol	Cosolvent and humectant	Supports minoxidil solubility	Irritation and allergic contact dermatitis
Purified water	Diluent	Low cost and patient familiarity	Can reduce solubility if improperly balanced
Glycerin	Humectant	May reduce dryness	Tackiness and slower drying
Polyethylene glycol	Cosolvent	Solubility support	Residue and sensory burden
Citric acid or citrate buffer	pH control	Product stability	Potential sting at low pH
Antioxidant	Oxidation control	May improve shelf life	Additional regulatory and compatibility burden
Chelating agent	Controls trace metals	Supports stability	Limited consumer-facing differentiation

Propylene glycol is a major formulation issue. It improves solubility but is associated with irritation and sensitization in some users. A propylene-glycol-free product can command a premium if it preserves minoxidil solubility, scalp tolerability, and shelf stability.

Foam excipients

Foam products generally use a volatile solvent system, surfactants, fatty alcohols, emulsifiers, propellants, and water. The foam vehicle can reduce the wet and greasy feel associated with liquid solutions and may improve adherence.

Potential foam excipient categories include:

• Ethanol or another volatile solvent
• Cetyl alcohol and stearyl alcohol as structural and emollient components
• Polysorbates or nonionic surfactants
• Glyceryl stearate or related emulsifiers
• Propellants such as hydrocarbons, subject to product and packaging requirements
• Purified water
• pH modifiers and stability agents

Foam products carry a higher manufacturing and packaging burden than simple solutions. They require compatibility testing between the formulation, valve, actuator, canister, and propellant system. The tradeoff is stronger cosmetic differentiation and potentially better consumer acceptance.

Which excipient strategy is strongest for Gainextra 5%?

A three-tier product strategy is commercially rational.

Tier 1: Cost-optimized conventional solution

The base product can use a conventional ethanol, propylene glycol, and water system. This approach minimizes manufacturing complexity and supports a competitive price.

The commercial limitation is weak differentiation. Products with similar active and excipient profiles compete primarily on brand recognition, retail placement, packaging, price, and consumer reviews.

Tier 2: Propylene-glycol-free solution

A propylene-glycol-free solution is a stronger opportunity. The formulation objective is to maintain 5% minoxidil solubility while reducing irritation and residue.

Potential approaches include:

• Higher ethanol content, balanced against dryness and sting
• Alternative glycol or polyethylene glycol systems
• Mixed solvent systems
• Solubilizing agents with lower sensitization potential
• Improved spray or pump delivery to reduce scalp runoff
• Controlled pH and water activity

The product should avoid implying that absence of propylene glycol guarantees superior tolerability. Clinical or consumer-use data would be needed to support tolerability claims.

Tier 3: Premium foam or low-residue delivery system

A foam, mousse, aerosol, or metered applicator offers the greatest commercial differentiation. The key benefits are faster drying, reduced hair matting, improved dose localization, and lower visible residue.

The principal risks are higher packaging cost, more complex scale-up, propellant regulation, and potential product loss through incorrect actuator use. A non-aerosol foam or mechanically generated foam could reduce some packaging and environmental concerns but may require more complex formulation engineering.

What formulations are protected by minoxidil patents?

The original minoxidil compound and basic topical use concepts are mature. A new product should not assume that the 5% concentration, topical scalp administration, or conventional ethanol-propylene-glycol vehicle can support meaningful patent exclusivity.

Potentially protectable subject matter includes:

1. A narrowly defined solvent system that achieves specified minoxidil solubility and stability.
2. A propylene-glycol-free composition with controlled precipitation limits.
3. A foam with defined particle size, collapse time, density, or deposition behavior.
4. A metered applicator that delivers a reproducible minoxidil dose.
5. A formulation that reduces scalp irritation while maintaining drug delivery.
6. A combination of minoxidil with a non-prescription cosmetic or dermatologic active, subject to FDA classification.
7. A packaging system that reduces oxidation, evaporation, or dose variability.
8. A manufacturing process that produces a stable supersaturated or controlled-release product.

Patent claims should be drafted around measurable technical parameters. Broad claims covering "a minoxidil composition with an acceptable solvent" are vulnerable to validity and obviousness challenges because the field contains extensive prior art.

How strong is the patent estate for Gainextra 5%?

The likely patent estate is weak at the active-ingredient level and potentially moderate at the formulation and delivery-system level.

Asset category	Likely strength	Reason
Minoxidil compound	Very low	Mature active ingredient
5% topical concentration	Very low	Widely used commercial concentration
Basic scalp-use method	Very low	Established indication and administration
Ethanol/propylene-glycol solution	Low	Conventional formulation architecture
Propylene-glycol-free vehicle	Moderate	Patentability depends on composition and performance data
Foam dosage form	Moderate	Claims may survive if technically narrow
Metered delivery device	Moderate to high	Device-specific claims can create differentiation
Stability and packaging system	Moderate	Stronger when tied to measurable shelf-life results
Combination product	Variable	Depends on active ingredients and regulatory classification
Brand and trade dress	Separate from patent	Potentially valuable commercial protection

Freedom-to-operate analysis should examine formulation, device, packaging, manufacturing, and method-of-use patents in the United States, Europe, Canada, Australia, Japan, and other target markets. A patent may have expired in the United States while remaining enforceable in another jurisdiction because of different filing dates, term adjustments, supplementary protection mechanisms, or national prosecution histories.

What is the FDA regulatory status of 5% topical minoxidil?

Topical minoxidil is regulated as an OTC drug. FDA’s OTC framework includes conditions relating to active ingredient concentration, labeling, indications, warnings, directions, and dosage form.[2]

A compliant product must address:

• Active ingredient identity and concentration
• Drug Facts labeling
• Age and population restrictions
• Directions for use
• Warnings concerning chest pain, rapid heartbeat, dizziness, unwanted facial hair, and other potential adverse effects
• Flammability or aerosol warnings where applicable
• Manufacturing under current good manufacturing practice requirements
• Stability and container-closure performance
• Product quality and microbial controls

A material change in formulation, dosage form, delivery system, or labeling may require a different regulatory strategy. A product that adds another active ingredient, claims treatment of a new disease, or makes stronger medical claims may fall outside the ordinary OTC framework.

What is the Orange Book status of Gainextra 5%?

A standard OTC minoxidil product is generally not expected to have a conventional Orange Book exclusivity position comparable to an approved prescription new drug.

The commercial consequences are significant:

• There is usually no meaningful new chemical entity exclusivity.
• Paragraph IV litigation is generally not the principal market-entry mechanism.
• Competitors can enter with equivalent OTC minoxidil products if they meet applicable regulatory and quality requirements.
• Brand protection depends more heavily on trademarks, retail distribution, formulation know-how, packaging, and consumer loyalty.
• An OTC monograph product does not ordinarily create a branded prescription-style patent cliff.

An exact Orange Book conclusion requires confirmation of the product’s FDA regulatory listing and marketing authorization structure. The product name alone does not establish an Orange Book listing.

When does Gainextra 5% lose exclusivity?

Gainextra 5% has no clear drug exclusivity date based solely on the product name. Minoxidil 5% is an established OTC active ingredient, so commercial exclusivity is likely to depend on non-patent assets rather than a statutory exclusivity period.

The practical exclusivity timeline is:

Period	Competitive condition
Launch phase	Brand, packaging, retailer placement, and consumer acquisition drive share
Early post-launch	Generic and private-label substitution limits pricing power
Differentiation phase	Proprietary vehicle, applicator, or packaging may support premium pricing
Mature phase	Scale, supply reliability, reviews, and distribution become decisive
Patent expiry phase	Relevant only if a new formulation or delivery patent is granted

Are there Paragraph IV challenges or generic entry risks?

Paragraph IV risk is likely limited because the product is not ordinarily protected through a prescription NDA patent listing. The dominant entry risk is direct substitution by other minoxidil 5% products.

Generic-entry scenarios include:

1. A lower-priced liquid solution with equivalent active concentration.
2. A private-label retailer product using a conventional vehicle.
3. A propylene-glycol-free competitor targeting irritated or sensitive scalps.
4. A foam product competing on convenience and cosmetic performance.
5. A subscription product using recurring delivery and digital adherence support.

A superior excipient system can slow substitution only if the consumer perceives a meaningful benefit, such as less itching, faster drying, lower residue, or easier dosing.

Which companies compete with 5% minoxidil products?

The competitive landscape includes branded OTC products, generic manufacturers, private-label retailers, telehealth companies, and hair-loss clinics. Major competitive reference products have historically included Rogaine and store-brand minoxidil products. The market also includes oral prescription treatments such as finasteride and low-dose oral minoxidil, although these products have different regulatory, safety, and prescribing profiles.

Competitor type	Principal advantage	Threat to Gainextra
Established branded minoxidil	Consumer trust and distribution	High
Store-brand solution	Low price	High
Branded foam	Better sensory profile	High
Telehealth platform	Diagnosis and recurring sales	Moderate to high
Hair-loss clinic	Integrated services	Moderate
Prescription finasteride	Different mechanism and clinical positioning	Indirect
Cosmetic scalp products	Lifestyle and appearance claims	Indirect

What licensing opportunities exist for Gainextra 5%?

Licensing opportunities are more likely to involve delivery technology than minoxidil itself.

Potential deal structures include:

• Exclusive rights to a propylene-glycol-free vehicle
• Regional rights to a foam technology
• Contract manufacturing and formulation transfer
• Co-development of a metered applicator
• Retailer-exclusive private-label supply
• Digital adherence licensing
• Combination products with cosmetic scalp-care systems
• International registration and commercialization rights

A license should distinguish ownership of the formulation, device, trademarks, regulatory dossier, manufacturing process, and market data. Royalty economics will be difficult to justify for an ordinary solution unless the license includes demonstrable performance, manufacturing cost advantages, or protected delivery technology.

What manufacturing and IP barriers affect commercial launch?

The main manufacturing barriers are not active-ingredient synthesis. They are formulation consistency, solvent control, packaging compatibility, fill accuracy, and stability.

Critical development work includes:

• Solubility and precipitation studies
• Accelerated and long-term stability testing
• Container-closure compatibility
• Pump and actuator dose uniformity
• Foam density and collapse testing
• Ethanol evaporation control
• Microbial and preservative evaluation
• Transport and temperature excursion studies
• Scale-up from laboratory mixing to commercial batches
• Human-factor testing for applicator use

A foam or metered system can create stronger IP protection but also increases capital requirements and supply-chain dependencies.

What revenue exposure and commercial upside exist?

Revenue exposure depends on retail price, repeat purchase rate, channel mix, and differentiation. A conventional solution is more exposed to price compression. A premium foam or low-irritation product can support higher gross margins, but only if repeat use remains high.

The most attractive commercial segments are:

• Consumers who discontinue standard solutions because of irritation
• Users who dislike greasy or wet scalp products
• Men seeking discreet, fast-drying treatment
• Subscription customers requiring automatic replenishment
• Retailers seeking differentiated private-label products
• International markets with limited access to premium foam products

A formulation that improves adherence can have greater commercial value than a formulation that merely changes excipient composition without improving user experience.

Key Takeaways

• Gainextra 5% is best analyzed as a topical minoxidil OTC product.
• Minoxidil compound and basic 5% topical-use patents offer little practical exclusivity.
• The strongest opportunities are propylene-glycol-free solutions, premium foams, metered applicators, and low-residue delivery systems.
• A conventional ethanol-propylene-glycol solution is commercially vulnerable to generic and private-label substitution.
• Orange Book and Paragraph IV exposure are likely limited for a standard OTC product.
• Formulation patents should rely on measurable technical performance, not broad claims covering ordinary minoxidil vehicles.
• Licensing value is more likely to reside in delivery technology, packaging, manufacturing know-how, or regional commercialization rights.
• Regulatory success depends on maintaining monograph-compliant labeling, dosage, concentration, and claims.
• Consumer adherence, sensory performance, and repeat purchase are the main commercial value drivers.

FAQs

Can Gainextra 5% be differentiated without changing the minoxidil concentration?

Yes. Differentiation can come from excipients, foam structure, applicator design, drying time, scalp residue, packaging, odor, and irritation performance.

Is propylene glycol necessary in a 5% minoxidil product?

No. It is common because it supports solubility, but alternative solvent systems may be developed. Any replacement must preserve solubility, stability, dose uniformity, and acceptable scalp tolerability.

Can a new Gainextra formulation receive a patent?

Possibly. Patentability is stronger for a specific solvent system, delivery device, stability profile, foam structure, or manufacturing process than for ordinary 5% minoxidil use.

Is a minoxidil foam automatically more effective than a solution?

No. Foam may improve cosmetic acceptability and adherence, but dosage accuracy, regular use, formulation performance, and consumer behavior determine real-world results.

Can Gainextra combine minoxidil with finasteride in an OTC product?

A minoxidil-finasteride combination would raise separate regulatory, safety, labeling, and intellectual-property issues. Finasteride is a prescription drug in the United States, so combining it with an OTC minoxidil product would not ordinarily remain within the standard OTC pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Minoxidil topical drug facts and consumer labeling. FDA.

2. U.S. Food and Drug Administration. (2022). OTC Monograph M032: Topical minoxidil drug products for over-the-counter human use. FDA.

3. U.S. Food and Drug Administration. (2024). Drug products marketed under the OTC monograph system. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.